Cyclerion Therapeutics, Inc. Common Stock (CYCN) Stock Price

CYCNStock

$4.00+57.83%52W

Market Cap$18.73M

P/E—

PEG Ratio—

Div yield—

Beta1.77

CYCN Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)179.87%

Price vs S&P 500 (4W)9.23%

VGM Score48.22

Book Value / Share (Quarterly)$1.60

P/TBV (Annual)0.48x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)8.36%

Cash Flow / Share (Quarterly)$-0.85

Price vs S&P 500 (YTD)197.49%

Net Profit Margin (TTM)-170.11%

EPS (TTM)$-1.37

10-Day Avg Trading Volume0.05M

EPS Excl Extra (TTM)$-1.37

Revenue Growth (5Y)-2.05%

EPS (Annual)$-1.11

ROI (Annual)-38.83%

Net Profit Margin (5Y Avg)-1544.15%

Cash / Share (Quarterly)$0.67

Revenue Growth QoQ (YoY)-43.24%

ROA (Last FY)-35.33%

Revenue Growth TTM (YoY)-4.23%

EBITD / Share (TTM)$-1.51

ROE (5Y Avg)-129.39%

Operating Margin (TTM)-176.28%

Cash Flow / Share (Annual)$-0.87

P/B Ratio2.73x

P/B Ratio (Quarterly)0.99x

Net Income / Employee (Annual)$-3,528,000

EV / Revenue (TTM)7.58x

Net Interest Coverage (TTM)-2581.50x

ROA (TTM)-55.14%

EPS Incl Extra (Annual)$-1.11

Current Ratio (Annual)5.15x

Quick Ratio (Quarterly)1.65x

3-Month Avg Trading Volume0.05M

52-Week Price Return57.83%

Revenue / Employee (TTM)$1,993,000

Tangible BV / Share (Quarterly)$5.26

P/S Ratio (Annual)8.94x

Asset Turnover (Annual)0.21x

52-Week High$8.48

Operating Margin (5Y Avg)-1581.10%

EPS Excl Extra (Annual)$-1.11

26-Week Price Return191.11%

Quick Ratio (Annual)4.72x

13-Week Price Return24.37%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)1.80x

Enterprise Value$15.72M

Revenue / Share Growth (5Y)-15.50%

Asset Turnover (TTM)0.21x

Book Value / Share Growth (5Y)-41.60%

Revenue / Employee (Annual)$2,074,000

Pretax Margin (Annual)-170.11%

Cash / Share (Annual)$0.85

3-Month Return Std Dev44.72%

Net Income / Employee (TTM)$-5,276,000

ROE (Last FY)-38.83%

EPS Basic Excl Extra (Annual)$-1.11

Receivables Turnover (TTM)6.86x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-1.37

Receivables Turnover (Annual)2.67x

ROI (TTM)-62.10%

P/S Ratio (TTM)8.94x

Pretax Margin (5Y Avg)-1544.15%

Revenue / Share (Annual)$0.65

Tangible BV / Share (Annual)$4.80

Price vs S&P 500 (52W)39.52%

Year-to-Date Return209.45%

5-Day Price Return-4.61%

EPS Normalized (Annual)$-1.11

ROA (5Y Avg)-87.45%

Net Profit Margin (Annual)-170.11%

Month-to-Date Return14.24%

Cash Flow / Share (TTM)$-7.92

EBITD / Share (Annual)$-1.15

Operating Margin (Annual)-176.28%

ROI (5Y Avg)-129.39%

EPS Basic Excl Extra (TTM)$-1.37

P/TBV (Quarterly)0.39x

P/B Ratio (Annual)0.55x

Pretax Margin (TTM)-170.11%

Book Value / Share (Annual)$2.38

Price vs S&P 500 (13W)21.57%

Beta1.77x

Revenue / Share (TTM)$0.47

ROE (TTM)-62.10%

52-Week Low$1.03

vGradeC

gGradeD

mGradeB

vgmGradeC

CYCN Earnings Surprise History

Q3 25-0.30est. —

Q4 25-0.19est. -0.38

CYCN Analyst Recommendations

Feb 2023

Mar 2023

Apr 2023

May 2023

4.14

Industry Peers — Pharmaceuticals(571)

Symbol	Value Score	Growth Score	Momentum Score	Price
CYCNCyclerion Therapeutics, Inc. Common Stock	C	D	B	$4.00
LLYEli Lilly & Co.	D	B	B	$1233.66
JNJJohnson & Johnson	D	C	B	$273.14
ABBVABBVIE INC.	D	C	B	$265.79
MRKMerck & Co., Inc.	D	C	A	$156.45
NVSNovartis AG	C	C	C	$159.98
AZNAstraZeneca PLC	C	B	C	$169.66
NVONovo-Nordisk A/S	B	C	C	$48.66
ABTAbbott Laboratories	C	C	B	$116.13
PFEPfizer Inc.	C	D	C	$28.57
VRTXVertex Pharmaceuticals Inc	D	C	B	$552.85
BMYBristol-Myers Squibb Co.	B	B	B	$67.92
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$46.02
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$52.07
REGNRegeneron Pharmaceuticals Inc	C	C	B	$833.56
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	C	$18.35
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$38.10
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	C	$376.37
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$62.07
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$240.08
ZTSZOETIS INC.	B	C	D	$77.29
INSMInsmed, Inc.	F	A	C	$123.89
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$36.47
UTHRUnited Therapeutics Corp	C	C	C	$518.53
GMABGenmab A/S ADS	C	C	B	$34.36
VTRSViatris Inc. Common Stock	B	C	B	$16.72
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$260.23
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$252.99
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$80.40
CORTCorcept Therapeutics Inc.	F	C	A	$123.57
BMRNBioMarin Pharmaceuticals Inc	C	C	C	$66.12
ARWRArrowhead Research Corporation	D	A	B	$88.88
ELANElanco Animal Health Incorporated Common Stock	C	B	B	$25.09
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	$512.16
CYTKCytokinetics Inc.	F	D	B	$77.46
AXSMAxsome Therapeutics, Inc	D	B	C	$205.48
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.36
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$63.57
ABVXAbivax SA American Depositary Shares	—	—	C	$117.93
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.34
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$368.02
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PTGXProtagonist Therapeutics, Inc	F	B	A	$150.59
SYRESpyre Therapeutics, Inc. Common Stock	—	—	A	$107.36
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.86
TGTXTG Therapeutics, Inc.	D	B	A	$55.42
ALKSAlkermes Inc. plc	D	C	B	$49.21
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$113.35
ORKAOruka Therapeutics, Inc. Common Stock	F	—	A	$101.82
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	$161.68
COGTCogent Biosciences, Inc. Common Stock	F	—	B	$36.80

About Cyclerion Therapeutics, Inc. Common Stock

Cyclerion Therapeutics is a clinical-stage biopharmaceutical company developing treatments for serious and orphan diseases using soluble guanylate cyclase (sGC) stimulator technology. The company's pipeline includes Olinciguat, Praliciguat, and other candidates targeting rare disease indications. Cyclerion is focused on advancing next-generation sGC stimulators to address unmet medical needs in patients with limited treatment options.